Cytocom, Inc., a private clinical-stage biopharmaceutical company developing novel immune modulating therapies targeting cancer, autoimmune, inflammatory, and infectious diseases based on proprietary platforms, today announced the acquisition of ImQuest Life Sciences, Inc., a research and development company focused specifically on cancer, inflammation and infectious disease treatments, including its subsidiaries in an all-stock transaction.
Market Data 
Markets 
AI
